Learn more

NANJING LEYANG PHARMACEUTICAL TECH CO LTD

Overview
  • Total Patents
    12
  • GoodIP Patent Rank
    136,911
About

NANJING LEYANG PHARMACEUTICAL TECH CO LTD has a total of 12 patent applications. Its first patent ever was published in 2019. It filed its patents most often in China. Its main competitors in its focus markets pharmaceuticals, biotechnology and basic materials chemistry are Yeda res & development co ltd, ZYCOS INC and DOBEEL CO LTD.

Patent filings in countries

World map showing NANJING LEYANG PHARMACEUTICAL TECH CO LTDs patent filings in countries
# Country Total Patents
#1 China 12

Patent filings per year

Chart showing NANJING LEYANG PHARMACEUTICAL TECH CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Zhou Tianbei 10
#2 Bi Xiaojuan 1
#3 Lu Yang 1
#4 Zhang Xuanwen 1
#5 Ma Chunhua 1
#6 Liu Yan 1

Latest patents

Publication Filing date Title
CN111575233A Culture medium for promoting CIK cell proliferation and improving killing power of CIK cell on tumor cells
CN111481549A Application of rhodinine B in preparation of anti-prostate cancer drugs
CN111358788A Application of dendrobium candidum pyridine base in preparation of colon cancer resisting medicine
CN111450092A Application of rhodinine B in preparation of anti-choriocarcinoma drug
CN111450090A Application of dendrobium candidum pyridine base in preparation of anti-nasopharyngeal carcinoma drugs
CN111467342A Application of rhodinine B in preparation of anti-nasopharyngeal carcinoma drugs
CN111450091A Application of dendrobium candidum pyridine in preparation of anti-choriocarcinoma drug
CN111388470A Application of dendrobium candidum pyridine base in preparation of anti-prostate cancer drugs
CN110693878A Application of dendrobine in preparing anti-multiple myeloma medicine
CN110693879A Application of dendrobine and composition thereof in resisting thyroid cancer
CN110357942A A kind of two peptide combinations and the application in terms of enhancing CIK cell activity
CN110192552A Application of the Glycyl-L-tyrosine conditioned medium in terms of mesenchymal stem cell cryopreserving and preparation commercialization freezing protective agent